
|Videos|September 21, 2017
What Are the Next Steps for Iclaprim?
Author(s)Contagion® Editorial Staff
David Huang, PhD, MD, explains what the next steps are for iclaprim, an antibiotic developed to treat patients with acute bacterial skin and skin structure infections.
Advertisement
David Huang, PhD, MD, chief medical officer at Motif Bio, explains what the next steps are for iclaprim, an antibiotic developed to treat patients with acute bacterial skin and skin structure infections. Dr. Huang shares that if the results of REVIVE 2 are favorable, then he and his team will submit a new drug application to the US Food and Drug Administration in the first half of next year.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
We are Losing the Current Battle With Measles as Well as the Long-Term War
2
Measles Update: January 30, 2026
3
Systematic Review of Antimicrobial Resistance in Bacterial Meningitis Caused by Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae
4
HIV Spending for Fiscal Year 2026: The Latest Update
5

































































































































